UnknownNot Applicable

Impact of Alpha Lipoic Acid Efficacy in Burning Mouth Syndrome

Italy60 participantsStarted 2020-01-20

Plain-language summary

A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of alpha lipoic acid (ALA) and determine the statistical significance of the outcome variables. Burning mouth syndrome (BMS) is defined as an oral burning sensation in the absence of clinical signs which could justify the syndrome. Recent studies suggest the existence of neurological factors as a possible cause of the disease.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * clinically diagnosed with BMS who reported a history of continuous oral burning pain for more than 4 months with no clinical signs that could justify the syndrome Exclusion Criteria: * clinically diagnosed with BMS who reported a history of continuous oral burning pain for more than 4 months with no clinical signs that could justify the syndrome

What they're measuring

Evolution of burning mouth

Timeframe: 6 months

Trial details

NCT IDNCT05729529

SponsorUniversity of Catania

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-25

Contact for this trial

Gaetano Isola

0953785652 gaetano.isola@unict.it

View on ClinicalTrials.gov More Burning Mouth Syndrome trials